Assay News and Research

RSS
FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN reports 20% revenue growth in first quarter 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

FDA approves Abbott Prism Chagas test to screen blood, tissue and organ donors for T. cruzi

FDA approves Abbott Prism Chagas test to screen blood, tissue and organ donors for T. cruzi

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

Gen-Probe reports total revenues of $135.4M for first-quarter 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

Study results from US Military Malaria Vaccine Program announced

Study results from US Military Malaria Vaccine Program announced

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

ExonHit to acquire RedPath for upfront payment of $12.5M in cash and $10M in stock

ATCC introduces CRMs for method validation and method-performance verification

ATCC introduces CRMs for method validation and method-performance verification

SQI Diagnostics signs development agreement with Silliker

SQI Diagnostics signs development agreement with Silliker

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

Study confirms utility of Oxford Immunotec's T-SPOT.TB assay in identifying latent TB infection

New reprogramming strategies needed for production of iPSCs: Study

New reprogramming strategies needed for production of iPSCs: Study

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.